Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors

A Survey from the Italian Association of Hemophilia Centers (AICE)

Antonio Coppola, Massimo Franchini, Giancarlo Castaman, Elena Santagostino, Cristina Santoro, Rita Carlotta Santoro, Massimo Morfini, Giovanni Di Minno, Angiola Rocino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothrombin complex concentrate [APCC] and recombinant activated factor VII [rFVIIa]) are available for the treatment and prevention of bleeding in inhibitor patients, their efficacy, safety, and cost–benefit outcomes are poorly known in the long term and should be further improved. In the frame of the update of recommendations for the management of inhibitor patients by the Italian Association of Hemophilia Centers (AICE), to collect more information on real-life therapeutic approaches with bypassing agents in this setting, a survey was conducted among the Directors of the Italian HTCs. From questionnaires returned by 55% of them, data on the use of rFVIIa and APCC in children, adolescent, and adult patients with hemophilia A and inhibitors were obtained and are summarized in this article, including information about the implementation of prophylaxis with both bypassing agents, the adopted regimens, and reasons for starting, adjusting, and interrupting such a therapeutic approach.

Original languageEnglish
Pages (from-to)551-560
JournalSeminars in Thrombosis and Hemostasis
Volume44
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Hemophilia A
Proxy
Therapeutics
Hemorrhage
Factor VIIa
Factor VIII
Neutralizing Antibodies
Surveys and Questionnaires
Morbidity
Physicians
Safety
Mortality

Keywords

  • activated prothrombin complex concentrate
  • bypassing agents
  • hemophilia A
  • inhibitors
  • prophylaxis
  • recombinant activated factor VII

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors : A Survey from the Italian Association of Hemophilia Centers (AICE). / Coppola, Antonio; Franchini, Massimo; Castaman, Giancarlo; Santagostino, Elena; Santoro, Cristina; Santoro, Rita Carlotta; Morfini, Massimo; Di Minno, Giovanni; Rocino, Angiola.

In: Seminars in Thrombosis and Hemostasis, Vol. 44, No. 6, 2018, p. 551-560.

Research output: Contribution to journalArticle

Coppola, Antonio ; Franchini, Massimo ; Castaman, Giancarlo ; Santagostino, Elena ; Santoro, Cristina ; Santoro, Rita Carlotta ; Morfini, Massimo ; Di Minno, Giovanni ; Rocino, Angiola. / Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors : A Survey from the Italian Association of Hemophilia Centers (AICE). In: Seminars in Thrombosis and Hemostasis. 2018 ; Vol. 44, No. 6. pp. 551-560.
@article{64befb0c91484a29a386d203ee5166af,
title = "Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE)",
abstract = "The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothrombin complex concentrate [APCC] and recombinant activated factor VII [rFVIIa]) are available for the treatment and prevention of bleeding in inhibitor patients, their efficacy, safety, and cost–benefit outcomes are poorly known in the long term and should be further improved. In the frame of the update of recommendations for the management of inhibitor patients by the Italian Association of Hemophilia Centers (AICE), to collect more information on real-life therapeutic approaches with bypassing agents in this setting, a survey was conducted among the Directors of the Italian HTCs. From questionnaires returned by 55{\%} of them, data on the use of rFVIIa and APCC in children, adolescent, and adult patients with hemophilia A and inhibitors were obtained and are summarized in this article, including information about the implementation of prophylaxis with both bypassing agents, the adopted regimens, and reasons for starting, adjusting, and interrupting such a therapeutic approach.",
keywords = "activated prothrombin complex concentrate, bypassing agents, hemophilia A, inhibitors, prophylaxis, recombinant activated factor VII",
author = "Antonio Coppola and Massimo Franchini and Giancarlo Castaman and Elena Santagostino and Cristina Santoro and Santoro, {Rita Carlotta} and Massimo Morfini and {Di Minno}, Giovanni and Angiola Rocino",
year = "2018",
doi = "10.1055/s-0038-1648230",
language = "English",
volume = "44",
pages = "551--560",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors

T2 - A Survey from the Italian Association of Hemophilia Centers (AICE)

AU - Coppola, Antonio

AU - Franchini, Massimo

AU - Castaman, Giancarlo

AU - Santagostino, Elena

AU - Santoro, Cristina

AU - Santoro, Rita Carlotta

AU - Morfini, Massimo

AU - Di Minno, Giovanni

AU - Rocino, Angiola

PY - 2018

Y1 - 2018

N2 - The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothrombin complex concentrate [APCC] and recombinant activated factor VII [rFVIIa]) are available for the treatment and prevention of bleeding in inhibitor patients, their efficacy, safety, and cost–benefit outcomes are poorly known in the long term and should be further improved. In the frame of the update of recommendations for the management of inhibitor patients by the Italian Association of Hemophilia Centers (AICE), to collect more information on real-life therapeutic approaches with bypassing agents in this setting, a survey was conducted among the Directors of the Italian HTCs. From questionnaires returned by 55% of them, data on the use of rFVIIa and APCC in children, adolescent, and adult patients with hemophilia A and inhibitors were obtained and are summarized in this article, including information about the implementation of prophylaxis with both bypassing agents, the adopted regimens, and reasons for starting, adjusting, and interrupting such a therapeutic approach.

AB - The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothrombin complex concentrate [APCC] and recombinant activated factor VII [rFVIIa]) are available for the treatment and prevention of bleeding in inhibitor patients, their efficacy, safety, and cost–benefit outcomes are poorly known in the long term and should be further improved. In the frame of the update of recommendations for the management of inhibitor patients by the Italian Association of Hemophilia Centers (AICE), to collect more information on real-life therapeutic approaches with bypassing agents in this setting, a survey was conducted among the Directors of the Italian HTCs. From questionnaires returned by 55% of them, data on the use of rFVIIa and APCC in children, adolescent, and adult patients with hemophilia A and inhibitors were obtained and are summarized in this article, including information about the implementation of prophylaxis with both bypassing agents, the adopted regimens, and reasons for starting, adjusting, and interrupting such a therapeutic approach.

KW - activated prothrombin complex concentrate

KW - bypassing agents

KW - hemophilia A

KW - inhibitors

KW - prophylaxis

KW - recombinant activated factor VII

UR - http://www.scopus.com/inward/record.url?scp=85047364388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047364388&partnerID=8YFLogxK

U2 - 10.1055/s-0038-1648230

DO - 10.1055/s-0038-1648230

M3 - Article

VL - 44

SP - 551

EP - 560

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 6

ER -